Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

@article{Moore2007ErlotinibPG,
  title={Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.},
  author={Malcolm J. Moore and David Goldstein and John Hamm and Ari{\'e} Figer and J. Randolph Hecht and Steven Gallinger and Heather J. Au and Paweł Murawa and David Walde and Robert A. Wolff and Daniel Campos and Robert C. Lim and Keyue Ding and Gary M. Clark and Theodora Voskoglou-Nomikos and Mieke Ptasynski and Wendy R. Parulekar},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 15},
  pages={
          1960-6
        }
}
  • M. Moore, D. Goldstein, +14 authors W. Parulekar
  • Published 20 May 2007
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. PATIENTS AND METHODS… 
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
  • P. Philip, J. Benedetti, +12 authors C. Blanke
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
In patients with advanced pancreas cancer, the anti-EGFR monoclonal antibody cetuximab did not improve the outcome compared with patients treated with gemcitabine alone, and alternate targets other than EGFR should be evaluated for new drug development.
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
TLDR
The addition of vandetanib to gemcitabine monotherapy did not improve overall survival in advanced pancreatic cancer and Tyrosine kinase inhibitors might still have potential in the treatment of pancreas cancer.
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
  • M. Sinn, M. Bahra, +18 authors H. Riess
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
TLDR
The CONKO-005 study is the first study to investigate the combination of chemotherapy and a targeted therapy in the adjuvant treatment of PDAC and found that adding erlotinib to gemcitabine did not improve DFS or overall survival over Gem.
Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
  • Sung Hee Lim, J. Yun, +11 authors Jong Ho Moon
  • Medicine
    Yonsei medical journal
  • 2021
TLDR
The addition of oxaliplatin to a first-line gemcitabine/erlotinib regimen demonstrated higher response rates and significantly improved PFS in patients with locally advanced or metastatic pancreatic cancer.
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
TLDR
Gemcitabine plus axitinib showed a similar safety profile to gem citabine alone; the small, non-statistically significant gain in overall survival needs to be assessed in a randomised phase III trial.
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
TLDR
The addition of bevacizumab to gemcitabine does not improve survival in advanced pancreatic cancer patients, and the only statistically significant differences in grades 3 and 4 toxicity occurred for hypertension and proteinuria.
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
TLDR
Dual EGFR‐directed therapy in combination with gem citabine alone cannot be recommended for further study, as single‐agent gemcitabine is no longer considered an appropriate therapy for otherwise fit patients with metastatic pancreatic cancer.
Optimal treatment of metastatic pancreatic cancer
TLDR
Preliminary results were encouraging, with a significantly longer OS, progression-free survival and improved response rate associated with the experimental arm compared with gemcitabine alone.
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
TLDR
The addition of bevacizumab to gemcitabine-erlotinib did not lead to a statistically significant improvement in OS in patients with metastatic pancreatic cancer; PFS, however, was significantly longer in the bevacsabine group compared with placebo, and safety data did not differ from previously described safety profiles for individual drugs.
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
TLDR
Skin rash strongly predicted erlotinib efficacy and PFS with GEC was not significantly different to that with GE in patients with mPC, while overall survival and OS were significantly longer in Patients with rash.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
TLDR
IRinOGEM safely improved the tumor response rate compared with GEM but did not alter overall survival, and subset analyses in patients with locally advanced disease suggested a TTP advantage with IRINOGEM versus GEM.
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
TLDR
5-FU, administered in conjunction with gemcitabine, did not improve the median survival of patients with advanced pancreatic carcinoma compared with single-agent gemcitABine, and clinical trial resources should address other combinations and novel agents.
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
TLDR
Cetuximab in combination with gemcitabine showed promising activity against advanced pancreatic cancer.
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
TLDR
TALENT was a placebo-controlled study in patients with previously untreated advanced NSCLC to receive erlotinib at 150mg/d or placebo (PBO) with 6 cycles of gemcitabine and cisplatin followed by monotherapy, with primary endpoint duration of survival.
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
TLDR
It is demonstrated that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer and confers a modest survival advantage over treatment with5-FU.
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
TLDR
A phase III study comparing GemOx with Gem alone in advanced pancreatic cancer, confirming the efficacy and safety of GemOx and failing to demonstrate a statistically significant advantage in terms of OS compared with Gem.
A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer
TLDR
This study evaluated the efficacy and toxicity of Gemcitabine in patients with resectable pancreatic cancer and found no significant difference between the groups after 6 weeks after operation.
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
TLDR
The results of this study provide no evidence to support a combination of marimastat with gemcitabine in patients with advanced pancreatic cancer and further studies of marIMastat as a maintenance treatment following a response or stable disease on gem citabine may be justified.
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
TLDR
Erlotinib was well tolerated in this heavily pretreated HNSCC population and produced prolonged disease stabilization; hence, further evaluation of its role in this tumor type is warranted.
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
TLDR
Pemetrexed plus gemcitabine therapy did not improve overall survival in patients with advanced pancreatic cancer, and single-agent gem citabine remains the standard of care for advanced Pancreatic cancer.
...
1
2
3
4
5
...